Histopathological investigation of glioblastomas resected under bevacizumab treatment

Ryota Tamura, Toshihide Tanaka, Keisuke Miyake, Yusuke Tabei, Kentaro Ohara, Oltea Sampetrean, Maya Kono, Katsuhiro Mizutani, Yohei Yamamoto, Yuichi Murayama, Takashi Tamiya, Kazunari Yoshida, Hikaru Sasaki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To date, no clinical observations have been reported for histopathological changes in human gliomas under antiangiogenic treatment. We collected six glioblastomas resected under bevacizumab treatment. Histopathological investigation was performed by hematoxilyn-eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, CA9, and nestin as compared to eleven control glioblastomas to assess the differences in histological features, microvessel density, expression of VEGF and its receptors, tumor oxygenation, and status of glioma stem-like cells. In the six tumors resected under bevacizumab, microvascular proliferation was absent, and microvessel density had significantly decreased compared with that of the controls. The expressions of VEGF and its receptors were downregulated in two cases of partial response. HIF-1α or CA9 expression was decreased in five of the six tumors, whereas the decreased expression of these markers was noted in only one of the 11 control glioblastomas. The expression of nestin significantly decreased in the six tumors compared with that of the controls, with the remaining nestin-positive cells being relatively concentrated around vessels. We provide the first clinicopathological evidence that antiangiogenic therapy induces the apparent normalization of vascular structure, decrease of microvessel density, and improvement of tumor oxygenation in glioblastomas. These in situ observations will help to optimize therapy.

Original languageEnglish
Pages (from-to)52423-52435
Number of pages13
JournalOncotarget
Volume7
Issue number32
DOIs
Publication statusPublished - 2016 Aug 1

Keywords

  • Bevacizumab
  • Glioma stem cell
  • Hypoxia
  • Neoadjuvant
  • Vascular normalization

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Histopathological investigation of glioblastomas resected under bevacizumab treatment'. Together they form a unique fingerprint.

  • Cite this

    Tamura, R., Tanaka, T., Miyake, K., Tabei, Y., Ohara, K., Sampetrean, O., Kono, M., Mizutani, K., Yamamoto, Y., Murayama, Y., Tamiya, T., Yoshida, K., & Sasaki, H. (2016). Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget, 7(32), 52423-52435. https://doi.org/10.18632/oncotarget.9387